Hydrogel-mediated bacteriophage therapy for pseudomonas aeruginosa biofilms in chronic wounds
Active Project Grant Awarded Last action
- Award ID
- F31AI200403
- Recipient
-
The Ohio State University UEI DLWBSLWAJWR1
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $77,988
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 0% complete
- Originally
- Place of performance
- Columbus, OH 43210, USA
Award details come from USAspending.gov.
Description
- Abstract
- /absrtact chronic wound infections remain a major clinical obstacle, primarily due to bacterial biofilm formation that drives antimicrobial tolerance and persistent infection. Among the most frequently encountered pathogens in these wounds is pseudomonas aeruginosa, and traditional treatment approaches such as debridement, antibiotics, and dressings, have proven ineffective in eliminating its biofilm. This project is therefore focused on developing and rigorously evaluating innovative therapies to address these treatment resistant wounds. Bacteriophages offer targeted antibacterial action with minimal toxicity and a low risk of driving resistance, making them strong candidates for localized treatment. However, their effectiveness is often limited by harsh wound conditions and by delivery approaches that do not provide sustained, protective release. Hydrogels offer an advantageous environment for stabilizing phages, protecting them from the adverse conditions of the wound and external environment, and allowing for their extended release at the infection site. Key questions remain about how phage stability, release, and antibacterial performance are affected within these materials. This proposal seeks to create and optimize a scalable framework for developing and characterizing phage-loaded hydrogels for chronic wounds. In aim 1, we will build robust and standardized methods to evaluate phage stability, activity, and release kinetics in a range of hydrogel and phage systems. Aim 2 will systematically compare the antibacterial efficacy of these optimized phage-hydrogel formulations with clinically relevant antimicrobial hydrogels, including the assessment of any synergistic or antagonistic effects. Aim 3 will assess how the wound environment influences phage-hydrogel performance by testing in a series of biologically relevant models, including bead biofilms, engineered human skin infections, and murine wound models. By fabricating and validating these new phage- hydrogel therapies, this project will advance our understanding of phage delivery in complex wound environments and provide practical, scalable methods to support future personalized optimization and clinical translation. The insights gained from this work are expected to shape new approaches to treating chronic, antibiotic-resistant wound infections and may inform strategies for antimicrobial delivery in other challenging infectious diseases.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $38,994 | |
| Amendment | $0 | |
| Original award | $38,994 |
Quick answers
Who received award F31AI200403?
F31AI200403 was awarded to The Ohio State University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on November 28, 2026.
How much is award F31AI200403 worth?
$77,988 has been obligated on F31AI200403.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award